Principal Financial Group Inc Mei Pharma, Inc. Transaction History

Principal Financial Group Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$0.41 - $0.64 $187 - $292	457 Added 3.06%	15,378 $6,000
Q2 2022 Aug 10, 2022	SELL	$0.42 - $0.65 $3,484 - $5,392	-8,296 Reduced 35.73%	14,921 $9,000
Q1 2022 May 09, 2022	BUY	$0.54 - $2.74 $2,578 - $13,083	4,775 Added 25.89%	23,217 $14,000
Q4 2021 Feb 09, 2022	SELL	$2.33 - $3.37 $10,491 - $15,175	-4,503 Reduced 19.63%	18,442 $49,000
Q3 2021 Nov 09, 2021	BUY	$2.52 - $2.99 $15,414 - $18,289	6,117 Added 36.35%	22,945 $63,000

Q2 2021 Aug 10, 2021	SELL	$2.6 - $3.65 $14,203 - $19,939	-5,463 Reduced 24.51%	16,828 $47,000
Q1 2021 May 10, 2021	SELL	$2.73 - $4.5 $6,977 - $11,502	-2,556 Reduced 10.29%	22,291 $76,000
Q4 2020 Feb 08, 2021	BUY	$2.6 - $3.32 $25,337 - $32,353	9,745 Added 64.53%	24,847 $66,000
Q3 2020 Nov 06, 2020	SELL	$2.46 - $4.27 $2,875 - $4,991	-1,169 Reduced 7.18%	15,102 $47,000
Q2 2020 Aug 05, 2020	BUY	$1.45 - $4.3 $4,537 - $13,454	3,129 Added 23.81%	16,271 $67,000
Q1 2020 May 12, 2020	BUY	$0.75 - $2.55 $2,016 - $6,856	2,689 Added 25.72%	13,142 $21,000
Q4 2019 Feb 05, 2020	SELL	$1.65 - $2.48 $1,920 - $2,886	-1,164 Reduced 10.02%	10,453 $26,000
Q3 2019 Nov 13, 2019	BUY	$1.48 - $2.52 $17,193 - $29,274	11,617 New	11,617 $20,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $373M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.